IJspeert H, Dalm V, van Zelm M, Edwards E
Immunother Adv. 2024; 4(1):ltae009.
PMID: 39679264
PMC: 11638974.
DOI: 10.1093/immadv/ltae009.
Hernandez-Lara M, Richard J, Deshpande D
Am J Physiol Lung Cell Mol Physiol. 2024; 327(1):L3-L18.
PMID: 38742284
PMC: 11380957.
DOI: 10.1152/ajplung.00091.2024.
Pinkerton J, Preite S, Piras A, Zervas D, Markou T, Freeman M
Respir Res. 2024; 25(1):175.
PMID: 38654248
PMC: 11040934.
DOI: 10.1186/s12931-024-02814-1.
Tzenaki N, Xenou L, Goulielmaki E, Tsapara A, Voudouri I, Antoniou A
Commun Biol. 2024; 7(1):26.
PMID: 38182748
PMC: 10770346.
DOI: 10.1038/s42003-023-05639-8.
Berglund L
J Clin Immunol. 2023; 44(1):34.
PMID: 38148368
PMC: 10751257.
DOI: 10.1007/s10875-023-01626-0.
PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.
Cant A, Chandra A, Munro E, Rao V, Lucas C
J Allergy Clin Immunol Pract. 2023; 12(1):69-78.
PMID: 37777067
PMC: 10872751.
DOI: 10.1016/j.jaip.2023.09.016.
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation.
Toskov V, Ehl S
Mol Cell Pediatr. 2023; 10(1):11.
PMID: 37702894
PMC: 10499775.
DOI: 10.1186/s40348-023-00167-1.
Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T, Lau A, Bier J, Cooke K, Lenthall H, Ruiz-Diaz S
J Exp Med. 2023; 220(6).
PMID: 36943234
PMC: 10037341.
DOI: 10.1084/jem.20221020.
PI3K Targeting in Non-solid Cancer.
Kim H, Ogana H, Sanchez V, Nichols C, Kim Y
Curr Top Microbiol Immunol. 2022; 436:393-407.
PMID: 36243854
PMC: 10075235.
DOI: 10.1007/978-3-031-06566-8_17.
PI3K Isoform Signalling in Platelets.
Schrottmaier W, Mussbacher M, Salzmann M, Kral-Pointner J, Assinger A
Curr Top Microbiol Immunol. 2022; 436:255-285.
PMID: 36243848
DOI: 10.1007/978-3-031-06566-8_11.
Class I PI3K Biology.
Aytenfisu T, Campbell H, Chakrabarti M, Amzel L, Gabelli S
Curr Top Microbiol Immunol. 2022; 436:3-49.
PMID: 36243838
DOI: 10.1007/978-3-031-06566-8_1.
PI3Kδ activity controls plasticity and discriminates between EMT and stemness based on distinct TGFβ signaling.
Agnetti J, Bou Malham V, Desterke C, Benzoubir N, Peng J, Jacques S
Commun Biol. 2022; 5(1):740.
PMID: 35879421
PMC: 9314410.
DOI: 10.1038/s42003-022-03637-w.
Lack of Functional P110δ Affects Expression of Activation Marker CD80 but Does Not Influence Functions of Neutrophils.
Manda-Handzlik A, Mroczek A, Kuzmicka W, Cieloch A, Homoncik Z, Muchowicz A
Int J Mol Sci. 2022; 23(12).
PMID: 35742807
PMC: 9223848.
DOI: 10.3390/ijms23126361.
Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
Ye H, Huang S, Liu Y, Chen Z, Wang M, Jiang V
J Cell Mol Med. 2022; 26(10):3068-3073.
PMID: 35352453
PMC: 9097828.
DOI: 10.1111/jcmm.17297.
Activated PI3Kδ syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model.
Serra I, Manusama O, Kaiser F, Floriano I, Wahl L, van der Zalm C
Brain Behav Immun Health. 2021; 18:100377.
PMID: 34786564
PMC: 8579111.
DOI: 10.1016/j.bbih.2021.100377.
Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita.
Zillikens H, Kasprick A, Osterloh C, Gross N, Radziewitz M, Hass C
Front Med (Lausanne). 2021; 8:713312.
PMID: 34557502
PMC: 8452940.
DOI: 10.3389/fmed.2021.713312.
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL.
Guarente V, Sportoletti P
Cancers (Basel). 2021; 13(6).
PMID: 33805745
PMC: 7999552.
DOI: 10.3390/cancers13061280.
P110α and P110δ catalytic subunits of PI3 kinase regulate lysophosphatidylcholine-induced TRPC6 externalization.
Chaudhuri P, Smith A, Putta P, Graham L, Rosenbaum M
Am J Physiol Cell Physiol. 2021; 320(5):C731-C741.
PMID: 33625929
PMC: 8163572.
DOI: 10.1152/ajpcell.00425.2020.
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?.
Aydin E, Faehling S, Saleh M, Llao Cid L, Seiffert M, Roessner P
Front Immunol. 2021; 11:595818.
PMID: 33552053
PMC: 7857022.
DOI: 10.3389/fimmu.2020.595818.
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.
Hu N, Wang F, Sun T, Xu Z, Zhang J, Bernard D
Clin Cancer Res. 2021; 27(8):2301-2313.
PMID: 33419778
PMC: 8046715.
DOI: 10.1158/1078-0432.CCR-20-3741.